{"name":"Aimmune Therapeutics, Inc.","slug":"aimmune-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":123987000,"netIncome":-248497000,"cash":79880000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AR101 - Peanut protein capsule","genericName":"AR101 - Peanut protein capsule","slug":"ar101-peanut-protein-capsule","indication":"Peanut allergy","status":"phase_2"},{"name":"AR101 powder provided in capsules","genericName":"AR101 powder provided in capsules","slug":"ar101-powder-provided-in-capsules","indication":"Peanut allergy","status":"phase_2"}]}],"pipeline":[{"name":"AR101 - Peanut protein capsule","genericName":"AR101 - Peanut protein capsule","slug":"ar101-peanut-protein-capsule","phase":"phase_2","mechanism":"AR101 works by desensitizing the immune system to peanut protein, allowing individuals with peanut allergies to safely consume peanuts.","indications":["Peanut allergy"],"catalyst":""},{"name":"AR101 powder provided in capsules","genericName":"AR101 powder provided in capsules","slug":"ar101-powder-provided-in-capsules","phase":"phase_2","mechanism":"AR101 is an oral immunotherapy for peanut allergy.","indications":["Peanut allergy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVWlhZTF3WHcwOWE5dGxjak5uQXBDN3FGSm9SaXkxaG1NdjYxQllQUjFaYkRpMXYtLTdZaHc3Wlk5TV9WbTBxS3VxUjNUOFJ2bkNybDZEb0dTRC0xYzV3eE1nZk1QNV8zcXplU0VVNG85UzEyT3BzaExnajltQVVFd1FNX0Q2X2lCODlXSGhnY1JDcE0?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Top Companies and Competitive Dynamics in the Allergy Immunotherapy Market - openPR.com","headline":"Top Companies and Competitive Dynamics in the Allergy Immunotherapy Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxObDVMUHp5dGc2ZUNhQnRyZHZJN0JLSnREVVJLeE54SnJqekVfaDI4eG9DcEJNQ0ZqZ29ScEwwZVljZmp6cFotY1VQLVhjdnEyb0xMel94aXp3X044cW5TZ1E1TnhaeVdGZU5QNU4xZi1MQkctNlFXck5NaFE4ZF9MMnc0djdOdENoUXhUOQ?oc=5","date":"2025-08-12","type":"pipeline","source":"Yahoo Finance","summary":"Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, Sanofi, ALK-Abello, Prota Therapeutics, Camallergy, Aravax, and Genentech - Yahoo","headline":"Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE84cmktYUtRYXN2U1lxdWVwaTNzLVhid1dmZE9UMC1RUGVNeGowRXE1ekJiWWpvZlJ5czRKMFkxRXhpVF9LZTFUdmt3NWlONlYyZVdwc19sQ2pmSEIzYjN4M2NB?oc=5","date":"2025-06-18","type":"pipeline","source":"PharmaTimes","summary":"Louise Peacock - PharmaTimes","headline":"Louise Peacock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQY0lWd1JMY3U1SzhTNWlLSGNMSUFGVDlMTlVpUDdXeXU3QV9HX1VvallwbWl1bUIxZmg2TXBhSkMwOTdWYldKeFpCVW9JcFc5WVZJUFY4Vk8yREk0UDZSbGlqZngwQ1lZSjBVNlI4ZGlncTdkYl8zdmdHa0c3T1p5TmhWYkNiVHE2eHowc3NnNEdobHNEdHc?oc=5","date":"2025-04-10","type":"pipeline","source":"Contract Pharma","summary":"Rivus Pharmaceuticals Expands Leadership Team - Contract Pharma","headline":"Rivus Pharmaceuticals Expands Leadership Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE9mUld1SFB6ZXF6VklxbmEwWDYwUWZEczBibjBZOGNibXVvaTU4WEVDZHBZXzBDdE5VT2l3THIwbVBHWEZIV2NGc0J2OWMwWmZtbnBzelVXNFgxTktSWjhCdWpvTk9zZw?oc=5","date":"2023-08-31","type":"pipeline","source":"Anton Health","summary":"Limited Distribution Updates - Anton Health","headline":"Limited Distribution Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxONm9QS1hhZTZqR2stVFFIU1pIMGc4Z2NUZ0JVT296TVpBeUtHZFVpWGVJQ3RHa0xyblJyOTRRN1JydlUyS2ktUmQ0a0ptVXNFVFJPcElfdlphX3I0dXBseDlJMF9ISmc2NHFKOTlROXBuMHNLT0dHa3NIeHg1LUVwQXFoak8yVFNSZDF2NnJtazBYcnBWWHhzSWN2VVM3NlEtX2l4LXEyQkJaTmVoWmRMNHVnODI1bURNR09oWDZSNFRjTVpBeFBIYkpHbTdVcmxKNjBhSnNNV2MxeDJEcGxTQjRVbms4MG02RTlIbGtRVzFLUXhHalRGU0tLX3MtZ2pYLTVzdHlZZTEzUlJJNTk3YXZ2SVY3TDUwRnd0enhoYTVXdXlkLWtVWXhLbVJXZXJLRV9Fcw?oc=5","date":"2022-10-13","type":"deal","source":"Business Wire","summary":"Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Directly to Patients - Business Wire","headline":"Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA® [Peanut (Arachis hypogaea) Alle","sentiment":"neutral"},{"date":"2020-10-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNekdLeGU5MDhLTURqUmd0aEhnVFlxeVdkMEMzN3U2YjlRMDdfZFh1TFBZcE5IN2dtWE0zaTNnNW05VHAyVU9sRXBxb3FhZ2t4V3R5Mkh5WWNXZk0xbUVycG9ubVNqdzBmeE1YLXVRUlpsSzVIOG9STDV0R0VXUlhsUmxEcXdnOURGd2NyeldNZmRXbnpaVllkeFgtaEFjYUpiR002bkVXX1NwZ0I2RUotbzB3?oc=5","date":"2020-10-14","type":"pipeline","source":"BioSpace","summary":"Aimmune Becomes Point Pharmaceutical Business for Nestlé - BioSpace","headline":"Aimmune Becomes Point Pharmaceutical Business for Nestlé","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTDhnNHZwQnZOUDFEMk96UkNGMlpjSWlGWXY0OXh0aEhVUV92VXB1QzFKZ29ZZlNfSjZNanlBdWVCU3BoSEZYal90VzA2b0Q3eHNSZWs2MXZJdkp1RzBsN0liUnJJWWNHbFQwOFJvN3preHdWbnlEaV9PMzNiRHJhbFZudndiVUU?oc=5","date":"2020-09-01","type":"deal","source":"Pharmaceutical Technology","summary":"Nestlé Health to acquire Aimmune Therapeutics for $2.6bn - Pharmaceutical Technology","headline":"Nestlé Health to acquire Aimmune Therapeutics for $2.6bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQRTQ2U2ExZzhHMXY1ems3NmdaYU1aVWxRUzV6YUxxNVJFXzlXSEFLNE9IZG1GbVdDWUhaczR0bnUxQXRjdWRvbEFaUHRicjlrTUZMTkNYX1NTNjFjR1lmSXpadGRuMjNta1VMaUFSLXQ5SkVoNFdseUMxcWlTeko2Z0J4cnFWSl9LZGp1UGt0ejJpaGVoMWfSAZsBQVVfeXFMT0lYc1NzQ2pPTlBvVHZuNlZyaXMtcHdCMUFVYlZSRUJHenVmRXRmajk5cXN5c19QWVRKd2VRMFd2NVhYeFdsVlpQM1c0MlBCcWFtUW03QmhkSzAwbjRDS1FCcFFzTjJPMnl3RWlmVl9ueE85bDBJRW9sancxUEppZkY3UXp5TjZxMUxhUmJXWjQ4eUZfdThQbkMyMVE?oc=5","date":"2020-08-31","type":"pipeline","source":"CNBC","summary":"Nestle pays $2 billion to secure Aimmune's allergy treatment - CNBC","headline":"Nestle pays $2 billion to secure Aimmune's allergy treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQQkE1dVNLVmtNM05Cc3NwQWZWSUMtaGJxVnVVUFlOdTFnbU1DSm5tNXJEcEZYZk16Z01xdXBJTXNwUy0xekU0ZVM3MFhnMUNiTTc0WU16djMxOVItdjBCR0cxOGduT2oxNl9UXzdvb2Y5Qmd1am04ZldnMEtWVVVpcC1ONUU4b21ONXNqdHEtMG5oX1Vzc1M2OGxsZmJNN1lzaUtlWkhtRXZjbXNTVE1ZVVRuamdGOG00UXdmQ3kyWDQ?oc=5","date":"2020-08-31","type":"deal","source":"Fierce Pharma","summary":"Nestlé plunks down $2.1B to acquire Aimmune and blockbuster hopeful peanut allergy med - Fierce Pharma","headline":"Nestlé plunks down $2.1B to acquire Aimmune and blockbuster hopeful peanut allergy med","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOOEVjUmUxeWpuWXd3YTF2WERhaU9WZnN5TVdpWnhXbDMwWWM1WVBhYmN1ZmlOVVZPdEVWbWpPeVlKQlFPYWpYaDExcG1TOWE2WklLRllrSmpMRlRhVUtTeG1RcTJLZWRMRDRiWkpPdFVCZ1laSkJ6ZDFZQTRRbW55eUFWNmdzM0xHb1RQYmxyaHZPdw?oc=5","date":"2020-08-31","type":"deal","source":"drugdiscoverytrends.com","summary":"Nestlé to acquire peanut allergy drugmaker for $2.6B - drugdiscoverytrends.com","headline":"Nestlé to acquire peanut allergy drugmaker for $2.6B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPYnZtYWlnSUhyN25LMDdNeUhNRHlkM3Q1aE1EcEZzZU54MVJ4QThja2t4SUttM1pONUVOOVQtMmJ4dmVjYnhlT1ZhMnNtWFpvcTNmMWZtSlBVWlpyMWpRV1doSDdYenF6QTRJRjZteW44cXZiSW1uaE82VG1IeVZwVmdNeEJONHE5NVI5QnQ3RmRaQW9UUDVXOVNBYmN4ZkFWVC1uVHh1Q3g0ek9tWUlNZXhrNGpLWG93SVc1VndISWhVMU15eEpHdjViWGRRQTh1ZGprbmxFUjFfYlhDc2pLck1qVWxoNThVc2FHWHlMNUtPTzdsLVNIWEFBRlNITDB5c2kwbXVhMjRmanpBN1hWU1ZIY0kwNk1YMUpEODFVVEducV9nVDBuOXltYjU?oc=5","date":"2017-06-07","type":"pipeline","source":"PR Newswire","summary":"CoreRx and Aimmune Therapeutics Joint Expansion to Create Pharmaceutical Jobs and Increase the Base of Scientific Capabilities in the Tampa Bay Area - PR Newswire","headline":"CoreRx and Aimmune Therapeutics Joint Expansion to Create Pharmaceutical Jobs and Increase the Base of Scientific Capabi","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":123987000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-248497000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":79880000,"cashHistory":[],"totalAssets":204369000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}